摘要
目的:观察硬化剂注射联合经导管动脉栓塞(TAE)治疗富血供型血管瘤患儿的效果。方法:回顾性分析2018年10月至2022年1月该院收治的103例富血供型血管瘤患儿的临床资料,根据治疗方法不同将其分为对照组(n=46)和研究组(n=57)。对照组给予TAE治疗,研究组在对照组基础上联合硬化剂注射治疗。比较两组临床疗效、血管瘤严重程度[血管瘤活动性和严重性评分量表(HASI)]评分和瘤体深度、不良反应发生率和1年复发率。结果:研究组治疗总有效率为94.74%(54/57),高于对照组的80.43%(37/46),差异有统计学意义(P<0.05);治疗后6个月,两组血管瘤严重程度评分和瘤体深度均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);治疗后1年,研究组复发率为1.75%(1/57),低于对照组的15.22%(7/46),差异有统计学意义(P<0.05)。结论:硬化剂注射联合TAE治疗富血供型血管瘤患儿可提高治疗总有效率,以及降低血管瘤严重程度评分、瘤体深度和1年复发率的效果优于单纯TAE治疗。
Objective:To observe effects of sclerosing agent injection combined with transcatheter arterial embolization(TAE)in treatment of children with hypervascular hemangioma.Methods:The clinical data of 103 children with hypervascular hemangioma admitted to the hospital from October 2018 to January 2022 were retrospectively analyzed.According to different treatment methods,they were divided into control group(n=46)and study group(n=57).The control group was treated with TAE,while the study group was treated with sclerosing agent injection on the basis of that of the control group.After 6 months of treatment,the clinical efficacies,the hemangioma severity[hemangioma activity and severity index(HASI)]score and the tumor depth,the incidence of adverse reactions,and the 1-year recurrence rate were compared between the two groups.Results:The total effective rate of the study group was 94.74%(54/57),which was higher than 80.43%(37/46)of the control group,and the difference was statistically significant(P<0.05).6 months after the treatment,the hemangioma severity scores and the tumor depth levels in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).1 year after the treatment,the recurrence rate of the study group was 1.75%(1/57),which was lower than 15.22%(7/46)of the control group,and the difference was statistically significant(P<0.05).Conclusions:Sclerosing agent injection combined with TAE in the treatment of the children with hypervascular hemangioma can improve the total effective rate of treatment,and reduce the severity scores of hemangioma,the tumor depth and the 1-year recurrence rate.Moreover,it is superior to simple TAE.
作者
代艳丽
刘博文
代升平
贺双华
DAI Yanli;LIU Bowen;DAI Shengping;HE Shuanghua(Department of Dermatology of Guancheng Hospital of TCM,Zhengzhou 450003 Henan,China;Ultrasound Diagnosis Department of Zhengzhou Yihe Hospital,Zhengzhou 450003 Henan,China;Department of Cardiology of Affiliated Hospital of Henan Academy of Chinese Medicine,Zhengzhou 450003 Henan,China)
出处
《中国民康医学》
2025年第7期68-70,共3页
Medical Journal of Chinese People’s Health
关键词
经导管动脉栓塞
硬化剂
注射
富血供型血管瘤
复发
Transcatheter arterial embolization
Sclerosing agent
Injection
Hypervascular hemangioma
Recurrence
作者简介
代艳丽(1977.09-),女,汉族,湖北随州人,本科,主治医师,研究方向为婴幼儿血管瘤、成人血管畸形的微创治疗。
